N-Chemiphar Adopts Seismic Isolation To Ensure Stable Japan Supply
This article was originally published in PharmAsia News
Executive Summary
Nippon Chemiphar will produce generic drugs at its in-house manufacturing plant with full seismic isolation to ensure the firm can meet the reliable supplies required by medical institutions, the company’s president Kazushiro Yamaguchi announced at a Tokyo press conference on July 9.